Diversify Wealth Management LLC Acquires Shares of 5,994 Ascendis Pharma A/S (NASDAQ:ASND)

Diversify Wealth Management LLC acquired a new position in shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 5,994 shares of the biotechnology company's stock, valued at approximately $998,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in the company. T. Rowe Price Investment Management Inc. grew its stake in Ascendis Pharma A/S by 54.4% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock worth $375,226,000 after buying an additional 960,504 shares during the last quarter. Capital International Investors boosted its stake in Ascendis Pharma A/S by 35.7% during the 4th quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after purchasing an additional 753,859 shares during the period. RA Capital Management L.P. grew its position in Ascendis Pharma A/S by 4.1% during the 4th quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Vestal Point Capital LP increased its stake in Ascendis Pharma A/S by 108.0% in the fourth quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company's stock valued at $71,588,000 after purchasing an additional 270,000 shares during the period. Finally, Janus Henderson Group PLC raised its holdings in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock valued at $602,910,000 after buying an additional 193,688 shares during the last quarter.

Ascendis Pharma A/S Stock Performance

Shares of ASND opened at $174.96 on Friday. Ascendis Pharma A/S has a fifty-two week low of $111.09 and a fifty-two week high of $183.00. The stock has a fifty day moving average of $168.27 and a two-hundred day moving average of $153.51. The company has a market capitalization of $10.70 billion, a PE ratio of -27.86 and a beta of 0.38.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last released its earnings results on Thursday, May 1st. The biotechnology company reported ($1.66) EPS for the quarter, missing the consensus estimate of ($1.56) by ($0.10). The company had revenue of $123.97 million during the quarter, compared to analysts' expectations of $98.56 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on ASND shares. Cantor Fitzgerald restated an "overweight" rating and issued a $200.00 price target on shares of Ascendis Pharma A/S in a research report on Monday, May 12th. Royal Bank Of Canada increased their price target on shares of Ascendis Pharma A/S from $205.00 to $210.00 and gave the stock an "outperform" rating in a report on Friday, May 2nd. Evercore ISI boosted their target price on shares of Ascendis Pharma A/S from $260.00 to $280.00 and gave the stock an "outperform" rating in a research report on Friday, May 2nd. Bank of America upped their price target on Ascendis Pharma A/S from $201.00 to $216.00 and gave the stock a "buy" rating in a report on Monday, June 9th. Finally, Morgan Stanley started coverage on Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price objective for the company. One analyst has rated the stock with a hold rating and fifteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $223.07.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.